Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Figg Website

William Douglas Figg Sr., Pharm.D.

Selected Publications

1)  Shahbazi S, Peer CJ, Polizzotto MN, Uldrick TS, Roth J, Wyvill KM, Aleman K, Zeldis JB, Yarchoan R, Figg WD.
A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses.
J Pharm Biomed Anal. 92: 63-8, 2014.
2)  Benazzi C, Al-Dissi A, Chau CH, Figg WD, Sarli G, de Oliveira JT, Gärtner F.
Angiogenesis in Spontaneous Tumors and Implications for Comparative Tumor Biology.
ScientificWorldJournal. 2014: 919570, 2014.
3)  Platz EA, Tangen CM, Goodman PJ, Till C, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Lucia MS, Thompson IM, Kristal AR.
Statin Drug Use Is Not Associated with Prostate Cancer Risk in Men who are Regularly Screened.
J. Urol. 2014.
4)  Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, Poondru S, Van Sant C, Keating A, Steinberg SM, Figg W, Giaccone G.
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
Ann. Oncol. 24: 2601-6, 2013.
5)  Vargesson N, Mahony C, Erskine L, Niven J, Greig NH, Figg WD.
Reply to D’Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos.
Proc. Natl. Acad. Sci. U.S.A. 110: E4820, 2013.
6)  Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N.
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation.
Proc. Natl. Acad. Sci. U.S.A. 106: 8573-8, 2009.
7)  Cook KM, Hilton ST, Mecinovic J, Motherwell WB, Figg WD, Schofield CJ.
Epidithiodiketopiperazines block the interaction between hypoxia inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism.
J. Biol. Chem. 2009.
8)  Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL.
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
J. Clin. Oncol. 28: 2070-6, 2010.
9)  Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD.
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Clin. Cancer Res. 18: 2099-107, 2012.
10)  Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL, Figg WD.
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Clin. Cancer Res. 14: 3312-8, 2008.
11)  Sissung T, Figg W.
Qing Y, eds.
Pharmacogenetics of Membrane Transporters: A Review of Current Approaches. In: Pharmacogenomics in Drug Discovery and Development.
Totowa: Humana Press; 2013. In Press. [Book Chapter]
12)  Basseville A, Bates S, Figg W, Sparreboom A.
Ishikawa T, Kim R, Konig J, eds.
Human ATP-binding Cassette Transproter ABCG2 (BCRP). In: Pharmacogenomics of Human Drug Transporters: Clinical Impacts.
Hoboken: John Wiley and Sons, Inc.; 2013. p. 311-344 [Book Chapter]
13)  Peer CJ, Brown JL, Martin TJ, Roth J, Spencer SD, Brassil P, McNeill KA, Kreisl TN, Fine HA, Figg WD.
A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 942-943: 107-12, 2013.
14)  Peer CJ, Rao M, Spencer SD, Shahbazi S, Steeg PS, Schrump DS, Figg WD.
A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 927: 142-6, 2013.
15)  Gao R, Reece KM, Sissung T, Fu SH, Venzon DJ, Reed E, Spencer SD, Price DK, Figg WD.
Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?.
BMJ Open. 3, 2013.
16)  Hall C, Troutman SM, Price DK, Figg WD, Kang MH.
Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.
Clin Genitourin Cancer. 11: 10-9, 2013.
17)  Duffy A, Zhao F, Haile L, Gamrekelashvili J, Fioravanti S, Ma C, Kapanadze T, Compton K, Figg WD, Greten TF.
Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies.
Cancer Immunol. Immunother. 62: 299-307, 2013.
18)  Noonan AM, Eisch RA, Liewehr DJ, Sissung TM, Venzon DJ, Flagg TP, Haigney MC, Steinberg SM, Figg WD, Piekarz RL, Bates SE.
Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for KATP channel.
Clin. Cancer Res. 19: 3095-104, 2013.
19)  Neuhouser ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes HL, Tao Y, Figg WD, Lucia MS, Hoque A, Hsing AW, Thompson IM, Pollak M.
Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial.
Cancer Prev Res (Phila). 6: 91-9, 2013.
20)  Goldspiel BR, Flegel WA, Dipatrizio G, Sissung T, Adams SD, Penzak SR, Biesecker LG, Fleisher TA, Patel JJ, Herion D, Figg WD, Lertora JJ, McKeeby JW.
Integrating pharmacogenetic information and clinical decision support into the electronic health record.
J Am Med Inform Assoc. 2013.
21)  Figg WD, Reid J.
Monitor tumor burden with circulating tumor DNA.
Cancer Biol. Ther. 14: 697-8, 2013.
22)  Moriyama B, Jarosinski PF, Figg WD, Henning SA, Danner RL, Penzak SR, Wayne AS, Walsh TJ.
Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.
Pharmacotherapy. 33: e19-22, 2013.
23)  Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC.
Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia.
Blood. 121: 476-84, 2013.
24)  Amiri-Kordestani L, Luchenko VL, Peer CJ, Ghafourian K, Reynolds J, Draper D, Frye R, Woo S, Venzon D, Wright JJ, Skarulis M, Figg WD, Fojo AT, Bates SE, Piekarz RL.
Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers.
Clin. Cancer Res. 2013.
25)  Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD.
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
BJU Int. 111: 1269-80, 2013.
26)  Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL.
Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity.
Clin Genitourin Cancer. 2013.
27)  Vaishampayan UN, Fontana J, Heilbrun LK, Smith D, Heath E, Dickow B, Figg WD.
Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer.
Urol. Oncol. 2013.
28)  Mahony C, Erskine L, Niven J, Greig NH, Figg WD, Vargesson N.
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro.
Proc. Natl. Acad. Sci. U.S.A. 110: 12703-8, 2013.
29)  Fernández EV, Price DK, Figg WD.
Prostate cancer progression attributed to autonomic nerve development: Potential for therapeutic prevention of localized and metastatic disease.
Cancer Biol. Ther. 14: 1005-6, 2013.
30)  Roth JE, Peer CJ, Price DK, Figg WD.
The androgen receptor transcriptional program in castration-resistant prostate cancer: Cell lines vs. tissue samples.
Cancer Biol. Ther. 15, 2013.
31)  Lewis J, Stephens S, Horenstein R, O'Connell J, Ryan K, Peer C, Figg W, Spencer S, Pacanowski M, Mitchell B, Shuldiner A.
The CYP2C19*17 Variant is not Independently Associated with Clopidogrel Response.
J. Thromb. Haemost. 2013.
32)  Lewis JP, Horenstein RB, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S, Bliden KP, Tantry US, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Gurbel PA, Shuldiner AR.
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.
Pharmacogenet. Genomics. 23: 1-8, 2013.
33)  Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M.
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.
Proc. Natl. Acad. Sci. U.S.A. 110: E1083-91, 2013.
34)  Johnson LM, Price DK, Figg WD.
Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy: implications for potential use of inhibitors in cancer treatment.
Cancer Biol. Ther. 14: 90-1, 2013.
35)  Martin TJ, Peer CJ, Figg WD.
Uncovering the genetic landscape driving castration-resistant prostate cancer.
Cancer Biol. Ther. 14: 399-400, 2013.
36)  Prager AJ, Peng CR, Lita E, McNally D, Kaushal A, Sproull M, Compton K, Dahut WL, Figg WD, Citrin D, Camphausen KA.
Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer.
Biomark Med. 7: 831-41, 2013.
37)  Reece K, Figg W.
UGT1A1 Polymorphisms and Mutation in Irinotecan-Induced Toxicity. In: Handbook of Therapeutic Biomarkers in Cancer.
2012. In Press. [Book Chapter]
38)  Chau C, Price D, Figg W.
Klein E, Jones J, eds.
Androgen Receptor CAG repeat length in prostate cancer. In: Management of Prostate Cancer, 3rd ed.
Totowa: Humana Press; 2012. In Press. [Book Chapter]
39)  Chau C, Figg W.
Abraham J, Gulley J, eds.
Novel Androgen Receptor Therapeutic Targets for Advanced Prostate Cancer. In: Emerging Cancer Therapeutics: Prostate Cancer.
New York: Demos Medical; 2012. p. 513-23 [Book Chapter]
40)  Gordon MS, Rosen LS, Mendelson D, Ramanathan RK, Goldman J, Liu L, Xu Y, Gerson SL, Anthony SP, Figg WD, Spencer S, Adams BJ, Theuer CP, Leigh BR, Weiss GJ.
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.
Invest New Drugs. 2012.
41)  Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G.
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Clin. Cancer Res. 18: 2344-51, 2012.
42)  Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS.
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
Clin. Cancer Res. 18: 4820-9, 2012.
43)  Peer CJ, Spencer SD, VanDenBerg DA, Pacanowski MA, Horenstein RB, Figg WD.
A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 880: 132-9, 2012.
44)  Chau CH, Figg WD.
Aflibercept in pediatric solid tumors: moving beyond the trap.
Clin. Cancer Res. 18: 4868-71, 2012.
45)  Chau CH, Figg WD.
Angiogenesis inhibitors increase tumor stem cells.
Cancer Biol Ther. 13: [Epub ahead of print], 2012.
46)  Kristal AR, Till C, Tangen CM, Goodman PJ, Neuhouser ML, Stanczyk FZ, Chu LW, Patel SK, Thompson IM, Reichardt JK, Hoque A, Platz EA, Figg WD, Van Bokhoven A, Lippman SM, Hsing AW.
Associations of serum sex steroid hormone and 5a-androstane-3a,17ß-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.
Cancer Epidemiol. Biomarkers Prev. 21: 1823-32, 2012.
47)  Huang X, Chau CH, Figg WD.
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.
J Hematol Oncol. 5: 35, 2012.
48)  Sissung TM, Reece KM, Spencer S, Figg WD.
Contribution of the OATP1B subfamily to cancer biology and treatment.
Clin. Pharmacol. Ther. 92: 658-60, 2012.
49)  Campbell TJ, Tindall DJ, Figg WD.
Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer.
Cancer Biol. Ther. 13: 237-8, 2012.
50)  Pratt E, Sissung TM, Figg WD.
Loss of OATP1B3 function causes Rotor syndrome: implications for potential use of inhibitors in cancer.
Cancer Biol. Ther. 13: 1374-5, 2012.
51)  Spencer S, Marini BL, Figg WD.
Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.
Anticancer Res. 32: 2391-8, 2012.
52)  Lancaster CS, Bruun GH, Peer CJ, Mikkelsen TS, Corydon TJ, Gibson AA, Hu S, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A.
OATP1B1 polymorphism as a determinant of erythromycin disposition.
Clin. Pharmacol. Ther. 92: 642-50, 2012.
53)  Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant S.
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl(+) hematological malignancies.
Cancer Chemother. Pharmacol. 69: 1657-67, 2012.
54)  Guo D, Cain JP, O'Connell S, Gardner ER, Pisle S, Figg WD, Tabibi SE, Yalkowsky SH.
Preformulation Study of NSC-726796.
AAPS PharmSciTech. 13: 661-73, 2012.
55)  Chen X, Peer CJ, Alfaro R, Tian T, Spencer SD, Figg WD.
Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.
J Pharm Biomed Anal. 62: 140-8, 2012.
56)  Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Adesunloye BA, Huang X, Karzai FH, Price DK, Figg WD.
Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.
Oncologist. 17: 312-20, 2012.
57)  Richardson ED, Price DK, Figg WD.
Significant addition to treatment options for bone metastasis in prostate cancer.
Cancer Biol. Ther. 13: 69-70, 2012.
58)  Sissung TM, Troutman SM, Campbell TJ, Pressler HM, Sung H, Bates SE, Figg WD.
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Discov Med. 13: 19-34, 2012.
59)  Chau C, Figg W.
DeVita V, Lwrence T, Rosenberg S, eds.
Pharmacology of Cancer Biotherapeutics: Angiogenesis Agents. In: Cancer: Principles and Practices of Oncology, 9th Edition.
Philadelphia: Lippincott Williams & Wilkins; 2011. p. 527-36 [Book Chapter]
60)  Figg W, Chau C.
Getting into Pharmacy School.
New York: Kaplan Publishing; 2011. [Book]
61)  Zhu W, Chau C, Gulley J, Dahut W, Figg W.
Chanan-Khan A, Lee K, eds.
Immunomodulating Drugs (IMiDs) for the Treatment of Prostate Cancer. In: Immunomodulating Drugs for the Treatment of Cancer.
Philadelphia: Lippincott Williams & Wilkins; 2011. p. 239-53 [Book Chapter]
62)  Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE.
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.
Clin. Cancer Res. 17: 569-80, 2011.
63)  Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannargudi B, Figg WD, Houk BE, Shnaidman M, Brega N, Giaccone G.
A Phase 1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas.
Clin Cancer Res. 17: 6831-9, 2011.
64)  Figg WD, Figg WD.
Cabazitaxel: filling one of the gaps in the treatment of prostate cancer.
Cancer Biol. Ther. 10: 1233-4, 2011.
65)  Peer CJ, Sissung TM, Figg WD.
CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents.
Cancer Biol. Ther. 11: 549-51, 2011.
66)  Franke RM, Lancaster CS, Peer CJ, Gibson AA, Kosloske AM, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A.
Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism.
Clin. Pharmacol. Ther. 89: 693-701, 2011.
67)  Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, Stein EV, Venzon D, Price DK, Figg WD.
Estrogen receptor alpha and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
J. Clin. Endocrinol. Metab. 96: E368-72, 2011.
68)  Pressler H, Sissung TM, Venzon D, Price DK, Figg WD.
Expression of OATP Family Members in Hormone-Related Cancers: Potential Markers of Progression.
PLoS ONE. 6: e20372, 2011.
69)  Sissung TM, Gardner ER, Piekarz RL, Howden R, Chen X, Woo S, Franke R, Clark JA, Miller-DeGraff L, Steinberg SM, Venzon D, Liewehr D, Kleeberger SR, Bates SE, Price DK, Rosing DR, Cabell C, Sparreboom A, Figg WD.
Impact of ABCB1 allelic variants on QTc interval prolongation.
Clin. Cancer Res. 17: 937-46, 2011.
70)  Figg W, Chau C.
Investments in Prostate Cancer Research are Starting to Pay Off.
Pharmacy Practice News. 40, 2011.
71)  Kummar S, Raffeld M, Juwara L, Horneffer YR, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey B, Choyke PL, Murgo AJ, Doroshow JH, Melillo G.
Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1{alpha} (HIF-1{alpha}) in Advanced Solid Tumors.
Clin Cancer Res. 17: 5123-31, 2011.
72)  Marti GE, Stetler-Stevenson M, Grant ND, White T, Figg WD, Tohnya T, Jaffe ES, Dunleavy K, Janik JE, Steinberg SM, Wilson WH.
Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia.
Leuk Lymphoma. 52: 2284-92, 2011.
73)  Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts JD, Grant S.
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms.
Clin Cancer Res. 17: 3388-3397, 2011.
74)  Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE.
Phase II trial of romidepsin in patients with peripheral T-cell lymphoma.
Blood. 117: 5827-34, 2011.
75)  Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD.
Population Pharmacokinetic Analysis of Sorafenib in Patients with Solid Tumors.
Br J Clin Pharmacol. 72: 294-305, 2011.
76)  Waldmann TA, Lugli E, Roederer M, Perera LP, Smedley JV, Macallister RP, Goldman CK, Bryant BR, Decker JM, Fleisher TA, Lane HC, Sneller MC, Kurlander RJ, Kleiner DE, Pletcher JM, Figg WD, Yovandich JL, Creekmore SP.
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.
Blood. 117: 4787-95, 2011.
77)  Pluta RM, Oldfield EH, Bakhtian KD, Fathi AR, Smith RK, Devroom HL, Nahavandi M, Woo S, Figg WD, Lonser RR.
Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers.
PLoS ONE. 6: e14504, 2011.
78)  Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, Tang L, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Thompson IM, Ambrosone CB, Hoque A.
Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.
Cancer Causes Control. 22: 1121-31, 2011.
79)  Sissung TM, Pressler H, Price DK, Figg WD.
SLCO Transport Genes in Prostate Cancer--Letter.
Cancer Epidemiol Biomarkers Prev. 20: 2325, 2011.
80)  Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW.
SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer.
J. Clin. Oncol. 29: 2565-73, 2011.
81)  Gao R, Reece K, Sissung T, Reed E, Price DK, Figg WD.
The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity.
Mutat. Res. 708: 21-7, 2011.
82)  Liang X, Guo Y, Figg WD, Fojo AT, Mueller MD, Yu JJ.
The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor.
Chemother Res Pract. 2011: 715469, 2011.
83)  Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T.
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
Clin. Cancer Res. 17: 907-17, 2011.
84)  Chau C, Figg W.
Kelly W, Halabi S, eds.
Preclinical Drug Assessment. In: Oncology Clinical Trials: Successful Design, Conduct and Analysis.
New York: Demos Medical; 2010. p. 21-27 [Book Chapter]
85)  Reece KM, Figg WD.
A novel regulator (USP10) of p53: Implications for tumor suppression and therapeutic targeting.
Cancer Biol. Ther. 9: 583-4, 2010.
86)  Figg WD, Woo S, Zhu W, Chen X, Ajiboye AS, Steinberg SM, Price DK, Wright JJ, Parnes HL, Arlen PM, Gulley JL, Dahut WL.
A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer.
J Urol. 183: 2219-26, 2010.
87)  Kummar S, Gutierrez ME, Gardner ER, Figg WD, Melillo G, Dancey J, Sausville EA, Conley BA, Murgo AJ, Doroshow JH.
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Cancer Chemother. Pharmacol. 65: 383-9, 2010.
88)  Clamp D, Yu J, Cho Y, Gao R, Jett J, Zot H, Cunnick J, Snyder B, Clump A, Shockey M, Gannett P, Coad J, Shurina R, Figg W, Reed E, Flynn D.
A Polymorphic Varation of AFAP-110 Enhances sSrc Activity.
Trans Oncol. 3: 276-85, 2010.
89)  English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL, Price DK, Figg WD.
A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer.
Ther Clin Risk Manag. 6: 579-83, 2010.
90)  Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW, Reichardt JK, Hoque A, Tangen CM, Kristal AR, Thompson IM, Figg WD.
Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.
J. Urol. 184: 2297-302, 2010.
91)  Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM, Figg WD.
Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
Prostate. 70: 584-90, 2010.
92)  Baum CE, Ockers SB, English BC, Price DK, Sartor O, Figg WD.
Androgen receptor sequence and variations in several common prostate cancer cell lines.
Cancer Biol Ther. 9: 383-8, 2010.
93)  Pressler HM, Figg WD.
Androgen synthesis and steroid transporters in prostate cancer: rethinking the transition to CRPC.
Cancer Biol. Ther. 9: 1043-5, 2010.
94)  Kluetz PG, Figg WD, Dahut WL.
Angiogenesis inhibitors in the treatment of prostate cancer.
Expert Opin Pharmacother. 11: 233-47, 2010.
95)  Cook KM, Figg WD.
Angiogenesis inhibitors: current strategies and future prospects.
CA Cancer J Clin. 60: 222-43, 2010.
96)  Gardner ER, Kelly M, Springman E, Lee KJ, Li H, Moore W, Figg WD.
Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
Invest New Drugs. 2010.
97)  Sun H, Pisle S, Gardner ER, Figg WD.
Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models.
Cancer Biol Ther. 10: 38-43, 2010.
98)  Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM.
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
J. Natl. Cancer Inst. 102: 1698-705, 2010.
99)  Sissung TM, English BC, Venzon D, Figg WD, Deeken JF.
Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.
Pharmacogenomics. 11: 89-103, 2010.
100)  Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R.
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.
BMC Cancer. 10: 511, 2010.
101)  Jain L, Gardner ER, Venitz J, Giaccone G, Houk BE, Figg WD.
Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878: 3187-92, 2010.
102)  Figg W, Smith E, Price D, English B, Thurman P, Steinberg S, Emanuel E.
Disclosing a Cancer Diagnosis: Where and How is it Occuring?.
J Clin Oncol. 28: 3630-5, 2010.
103)  Hulin-Curtis SL, Petit D, Figg WD, Hsing AW, Reichardt JK.
Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer.
Future Oncol. 6: 1897-913, 2010.
104)  Gao R, Price D, Dahut W, Steinberg S, Reed E, Figg W.
Genetic Polymorphisms in XRCC1 associated with Radiation Therapy in Prostate Cancer.
Cancer Biol Ther. 10: 13-8, 2010.
105)  Kirkland C, Price D, Figg W.
Genetic Variant Associated with Aggressive not Indolent Prostate Cancer.
Cancer Biol Ther. 9: 957-8, 2010.
106)  Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD.
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
J. Exp. Clin. Cancer Res. 29: 95, 2010.
107)  Smith NF, Mani S, Schuetz EG, Yasuda K, Sissung TM, Bates SE, Figg WD, Sparreboom A.
Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.
Ann Pharmacother. 44: 1709-17, 2010.
108)  Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, Robey RW, Turner M, Gardner ER, Figg WD, Steinberg SM, Ling A, Fojo T, To KW, Piekarz RL.
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.
Br. J. Haematol. 148: 256-67, 2010.
109)  Jain L, Gardner ER, Figg WD, Chernick MS, Kong HH.
Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.
Pharmacotherapy. 30: 52-6, 2010.
110)  Ajiboye S, Sissung TM, Sharifi N, Figg WD.
More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.
BJU Int. 105: 913-6, 2010.
111)  Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, Figg WD.
Pharmacogenetics of membrane transporters: an update on current approaches.
Mol. Biotechnol. 44: 152-67, 2010.
112)  Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgo AJ.
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
Eur. J. Cancer. 46: 340-7, 2010.
113)  Troutman SM, Price DK, Figg WD.
Prostate cancer genomic signature offers prognostic value.
Cancer Biol. Ther. 10: 1079-80, 2010.
114)  Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, Gardner ER, Figg WD, Bates SE.
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
Expert Rev Anticancer Ther. 10: 997-1008, 2010.
115)  Baum CE, Price DK, Figg WD.
Sarcosine as a potential prostate cancer biomarker and therapeutic target.
Cancer Biol Ther. 9: 341-2, 2010.
116)  Sharma H, Sissung TM, Pressler H, Figg WD.
Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism.
Cancer Biol. Ther. 9: 163-5, 2010.
117)  Sharifi N, Qi J, Bane S, Sharma S, Li R, Robey R, Figg WD, Farrar WL, Kingston DG.
Survivin is not induced by novel taxanes.
Mol. Pharm. 7: 2216-23, 2010.
118)  Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia MS, Platz EA, Figg WD, Hoque A, Hsing A, Neuhouser ML, Parnes HL, Reichardt JK, Santella RM, Till C, Lippman SM.
Transition of a clinical trial into translational research: the prostate cancer prevention trial experience.
Cancer Prev Res (Phila). 3: 1523-33, 2010.
119)  Figg W.
When Does a Malpractice Error Become a Felony?.
Pharmacotherapy. Alternative Viewpoints - May, 2010.
Full Text Article. [Journal]
120)  Figg W, Chau C.
Getting into Pharmacy School, 2nd Ed.
New York: Kaplan Publishing; 2009. [Book]
121)  Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL.
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
J. Urol. 181: 1104-13; discussion 1113, 2009.
122)  Jonsson JG, Sissung TM, Figg WD.
A genomic strategy for predicting androgen receptor activity in prostate tumors.
Cancer Biol. Ther. 8: 2002-3, 2009.
123)  Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, Liewehr DJ, Dahut WL, Miao X, Figg WD.
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
Pharmacogenomics J. 10: 191-9, 2009.
124)  Azad N, Perroy A, Gardner E, Imamura CK, Graves C, Sarosy GA, Minasian L, Kotz H, Raggio M, Figg WD, Kohn EC.
A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.
Cancer Biol. Ther. 8: 1800-5, 2009.
125)  Pisle ST, Figg WD.
Antiandrogens in the 21st century.
Cancer Biol. Ther. 8: 1611, 2009.
126)  Gardner E, Figg W.
Book Review: Review of Genomics and pharmacogenomics in anticancer drug development and clinical response.
Clin Pharmacol Ther. 85: 124-125, 2009.
127)  Sissung TM, Thordardottir S, Gardner ER, Figg WD.
Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.
Anticancer Agents Med Chem. 9: 1058-69, 2009.
128)  Danish M, Gardner ER, Chen X, Figg WD.
Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877: 355-9, 2009.
129)  Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, Draper D, Venitz J, Jones E, Chen CC, Figg WD, Dahut WL.
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
BJU Int. 103: 1636-40, 2009.
130)  Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, Steinberg SM, Turner ML, Kohn EC, Kong HH.
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Clin. Cancer Res. 15: 1411-6, 2009.
131)  Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H, Figg WD, Dahut WL.
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Cancer Invest. 27: 221-6, 2009.
132)  Gardner ER, Smith NF, Figg WD, Sparreboom A.
Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.
J. Exp. Clin. Cancer Res. 28: 99, 2009.
133)  Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM, Kristal AR.
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.
Cancer Epidemiol. Biomarkers Prev. 18: 2807-13, 2009.
134)  Wolfe ME, Yagoda D, Thurman PW, Luna JM, Figg WD.
NCI designated cancer center funding not influenced by organizational structure.
Cancer Biol. Ther. 8: 869-73, 2009.
135)  Chau CH, Figg WD.
New tricks from an old drug: a role for quinacrine in anti-cancer therapy?.
Cell Cycle. 8: 4024-5, 2009.
136)  Dahut WL, Aragon-Ching JB, Woo S, Tohnya TM, Gulley JL, Arlen PM, Wright JJ, Ventiz J, Figg WD.
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Journal of clinical pharmacology. 49: 650-60, 2009.
137)  Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE.
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
J. Clin. Oncol. 27: 5410-7, 2009.
138)  Pressler H, Figg WD.
Phenotypic approach to drug discovery.
Cancer Biol. Ther. 8: 11-2, 2009.
139)  Mucci LA, Stark JR, Figg WD, Schumacher F, Li H, Abe M, Hennessy K, Stampfer MJ, Gaziano JM, Ma J, Kantoff PW.
Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study.
Int. J. Cancer. 125: 1143-6, 2009.
140)  Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, Price DK, Frye R, Piekarz RL, Bates SE, Figg WD.
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
Clin. Cancer Res. 15: 1496-503, 2009.
141)  Luna JM, Thurman PW, Wolfe M, Yagoda D, Reed E, Figg WD.
Private Practice Administrative Costs Influenced by Insurance Payer Mix.
J Oncol Pract. 5: 291-297, 2009.
142)  Ning YM, Figg WD, Dahut WL.
Reversal of Docetaxel Resistance With Bevacizumab and Thalidomide.
Clinical genitourinary cancer. 7: E37-E38, 2009.
143)  Stein EV, Price DK, Figg WD.
shRNA technology: investigating Ras-dependent cancer.
Cancer Biol. Ther. 8: 1798-9, 2009.
144)  Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J, Figg WD.
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.
Mol. Cancer Ther. 8: 2496-508, 2009.
145)  Zhu W, Zhu DS, Madan RA, Gulley JL, Figg WD, Dahut WL.
Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway.
Am J Ther. 17: 176-81, 2009.
146)  Flowers L, Wick J, Figg WD, McClelland RH, Shiber M, Britton JE, Ngo DK, Borders-Hemphill V, Mead C, Zee J, Huntzinger P.
U.S. Public Health Service Commissioned Corps pharmacists: making a difference in advancing the nation's health.
Journal of the American Pharmacists Association : JAPhA. 49: 446-52, 2009.
147)  Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, Smith S, Shankavaram U, Kaushal A, Figg WD, Dahut W, Citrin D, Bottaro DP, Albert PS, Tofilon PJ, Camphausen K.
Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.
Clin. Cancer Res. 15: 4292-8, 2009.
148)  English BC, Price DK, Figg WD.
VEGF inhibition and metastasis: Possible implications for antiangiogenic therapy.
Cancer Biol. Ther. 8, 2009.
149)  Figg W, Folkman J, eds.
Angiogenesis: An Integrative Approach from Science to Medicine.
Boston: Springer; 2008. [Book (Editor)]
150)  Chau C, Dahut W, Figg W.
Figg W, Folkman J, eds.
Development of Thalidomide and Its IMiD Derivatives. In: Angiogenesis: An Integrative Approach from Science to Medicine. Volume Chapter 34.
Boston: Springer; 2008. p. 387 [Book Chapter]
151)  Chau C, Figg W.
Figg W, Folkman J, eds.
Recent Advances in Angiogenesis Drug Development. In: Angiogenesis: An Integrative Approach from Science to Medicine. Volume Chapter 37.
Boston: Springer; 2008. p. 421 [Book Chapter]
152)  Chau C, Figg W.
DePinho R, Weinberg R, eds.
Angiogenesis Therapy. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. Volume 2.
Philadelphia: Lippincott Williams & Wilkins; 2008. p. 3,200 [Book Chapter]
153)  Sissung T, Gardner E, Gao R, Figg W.
Yan Q, eds.
Pharmacogenetics of Membrane Transporters: A Review of Current Approaches. In: Pharmacogenomics in Drug Discovery and Development. Volume 448.
New Jersey: Humana Press; 2008. p. 41-62 [Book Chapter]
154)  Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC, Figg WD.
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Clin. Cancer Res. 14: 209-14, 2008.
155)  Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, Gulley JL, Price DK, Dahut WL, Figg WD.
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
BJU Int. 2008.
156)  Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg WD.
ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel.
Clin. Cancer Res. 14: 4543-4549, 2008.
157)  Gardner ER, Ahlers CM, Shukla S, Sissung TM, Ockers SB, Price DK, Hamada A, Robey RW, Steinberg SM, Ambudkar SV, Dahut WL, Figg WD.
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.
BJU Int. 2008.
158)  Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A.
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.
Mol. Cancer Ther. 7: 19-26, 2008.
159)  Li H, Raia V, Bertolini F, Price DK, Figg WD.
Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
BJU Int. 101: 884-8, 2008.
160)  Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Kruchin E, Wright JJ, Rosing DR, Sparreboom A, Figg WD, Steinberg SM.
Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Clin. Cancer Res. 14: 188-98, 2008.
161)  Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, Multani AS, Lim S, Coleman IM, Wu LC, Figg WD, Dahut WL, Nelson P, Lee JK, Amin MB, Lyles R, Johnstone PA, Marshall FF, Chung LW.
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis.
Cancer Res. 68: 9996-10003, 2008.
162)  Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N, Imbimbo C, Perdonà S, Giordano A, Giuliano M, Labianca R, De Placido S.
Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study.
Eur. Urol. 2008.
163)  Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC.
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
J. Clin. Oncol. 26: 3709-14, 2008.
164)  Ge Y, Byun JS, De Luca P, Gueron G, Li QQ, Yabe IM, Sadiq-Ali SG, Figg WD, Quintero J, Haggerty CM, De Siervi A, Gardner K.
Combinatorial anti-leukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide CPS49 and flavopiridol.
Mol. Pharmacol. 2008.
165)  Chau CH, Wang W, Figg WD.
Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis.
Cancer Biol. Ther. 7, 2008.
166)  Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M.
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
J. Clin. Oncol. 26: 1148-59, 2008.
167)  Chen X, Gardner ER, Figg WD.
Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 865: 153-8, 2008.
168)  Chen X, Gardner ER, Price DK, Figg WD.
Development and validation of an LC-MS assay for finasteride and its application to prostate cancer prevention trial sample analysis.
J Chromatogr Sci. 46: 356-61, 2008.
169)  Jain L, Gardner ER, Venitz J, Dahut W, Figg WD.
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.
J Pharm Biomed Anal. 46: 362-7, 2008.
170)  Gao R, Price DK, Sissung T, Reed E, Figg WD.
Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1.
Mol. Cancer Ther. 7: 1246-50, 2008.
171)  Hoque A, Goodman P, Ambrosone CB, Figg WD, Price DK, Kopp W, Wu X, Conroy J, Lehman TA, Santella RM.
Extraction of DNA from serum for high-throughput genotyping: findings from pilot studies within the Prostate Cancer Prevention Trial.
Urology. 71: 967-70, 2008.
172)  Danish M, Sissung T, Price DK, Figg WD.
Genetic stability of tumor microenvironment.
Cancer Biol. Ther. 7: 1-2, 2008.
173)  Gulley JL, Aragon-Ching JB, Steinberg SM, Hussain MH, Sartor O, Higano CS, Petrylak DP, Chatta GS, Arlen PM, Figg WD, Dahut WL.
Kinetics of Serum Androgen Normalization and Factors Associated With Testosterone Reserve After Limited Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer.
J. Urol. 2008.
174)  Gardner ER, Sparreboom A, Verweij J, Figg WD.
Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib.
Cancer Biol. Ther. 7: 412-5, 2008.
175)  Smith NF, Baker SD, Gonzalez FJ, Harris JW, Figg WD, Sparreboom A.
Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.
Br. J. Cancer. 98: 1630-2, 2008.
176)  Chu Z, Chen JS, Liau CT, Wang HM, Lin YC, Yang MH, Chen PM, Gardner ER, Figg WD, Sparreboom A.
Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.
Anticancer Drugs. 19: 275-81, 2008.
177)  Figg WD, Chau CH, Okita R, Preusch P, Tracy TS, McLeod H, Reed M, Pieper J, Knoell D, Miller K, Speedie M, Blouin R, Kroboth P, Koda-Kimble MA, Taylor P, Cohen J, Giacomini K.
Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy research.
Pharmacotherapy. 28: 821-33, 2008.
178)  Sissung TM, Gardner ER, Gao R, Figg WD.
Pharmacogenetics of membrane transporters: a review of current approaches.
Methods Mol. Biol. 448: 41-62, 2008.
179)  Jain L, Figg W.
Polypharmacy in View of Advances in Cancer Treatment.
The Oncology. 22: 1055-63, 2008.
180)  Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O.
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
J. Urol. 179: 2181-5; discussion 2185-6, 2008.
181)  Gardner ER, Dahut W, Figg WD.
Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 862: 213-8, 2008.
182)  Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD.
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
Clin. Cancer Res. 14: 4200-5, 2008.
183)  Wang W, Figg WD.
Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
Cancer Biol. Ther. 7: 1004-5, 2008.
184)  Sharifi N, Dahut WL, Figg WD.
Secondary hormonal therapy for prostate cancer: what lies on the horizon?.
BJU Int. 101: 271-4, 2008.
185)  Miles RJ, Price DK, Figg WD.
Temporal-mediated FGFR1 independence: implications for targeting candidate molecules in prostate cancer.
Cancer Biol. Ther. 7: 1180-1, 2008.
186)  Sharifi N, Dahut WL, Figg WD.
The genetics of castration-resistant prostate cancer: what can the germline tell us?.
Clin. Cancer Res. 14: 4691-3, 2008.
187)  Figg WD.
The Pharm.D. investigator in clinical pharmacology: supply and demand.
Clin. Pharmacol. Ther. 84: 526-9, 2008.
188)  Stein WD, Figg WD, Dahut W, Stein AD, Hoshen MB, Price D, Bates SE, Fojo T.
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.
Oncologist. 13: 1046-54, 2008.
189)  Chau CH, Rixe O, McLeod H, Figg WD.
Validation of analytic methods for biomarkers used in drug development.
Clin. Cancer Res. 14: 5967-76, 2008.
190)  Figg W, Chau C, eds.
Get into Pharmacy School: Rx for Success!.
New York: Kaplan Publishing; 2007. [Book (Editor)]
191)  Fine HA, Kim L, Albert PS, Duic JP, Ma H, Zhang W, Tohnya T, Figg WD, Royce C.
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
Clin. Cancer Res. 13: 7101-6, 2007.
192)  Li H, Price DK, Figg WD.
ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer.
Anticancer Drugs. 18: 563-8, 2007.
193)  Sharifi N, Figg WD.
Androgen receptor modulation: lessons learned from beyond the prostate.
Cancer Biol. Ther. 6: 1358-9, 2007.
194)  Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D, Sparreboom A, Dahut WL, Figg WD.
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.
Urology. 70: 217-20, 2007.
195)  Al-Chalabi T, Figg WD.
Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients.
Cancer Biol. Ther. 6: 318-9, 2007.
196)  Lakhani NJ, Sparreboom A, Xu X, Veenstra TD, Venitz J, Dahut WL, Figg WD.
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol.
Journal of pharmaceutical sciences. 96: 1821-31, 2007.
197)  Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD.
CYP2D6 polymorphisms and the impact on tamoxifen therapy.
J Pharm Sci. 2007.
198)  Chen X, Gardner ER, Gutierrez M, Kummar S, Figg WD.
Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 858: 302-6, 2007.
199)  Di Lorenzo G, Autorino R, Perdonà S, De Laurentiis M, D'Armiento M, Cancello G, Mirone V, Imbimbo C, Longo N, Altieri V, Tortora G, Figg WD, De Placido S.
Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study.
Eur Urol. 2007.
200)  Di Lorenzo G, Autorino R, Figg WD, De Placido S.
Hormone-Refractory Prostate Cancer : Where are We Going?.
Drugs. 67: 1109-24, 2007.
201)  Aragon-Ching JB, Gillespie J, Price DK, Chuaqui R, Rodriguez-Canales J, Steinberg SM, Dahut WL, Figg WD.
Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer.
BJU Int. 100: 1245-8, 2007.
202)  Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA.
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
Clin. Cancer Res. 13: 5183-94, 2007.
203)  Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PC, Figg WD, Lee EJ, Chowbay B.
Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients.
Pharmacogenomics. 8: 567-575, 2007.
204)  Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S, Tidwell ML, Greer J, Chung EJ, Lee MJ, Gore SD, Sausville EA, Zwiebel J, Karp JE.
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Blood. 109: 2781-90, 2007.
205)  Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, Figg WD, Trepel JB, Zwiebel J, Doroshow JH, Murgo AJ.
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Clin. Cancer Res. 13: 5411-7, 2007.
206)  Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W.
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
BJU Int. 99: 1047-55, 2007.
207)  Wu SL, Jones E, Gulley JL, Arlen PM, Chen CC, Figg WD, Dahut WL.
Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
BJU Int. 99: 525-8, 2007.
208)  Aragon-Ching JB, Li H, Gardner ER, Figg WD.
Thalidomide analogues as anticancer drugs.
Recent patents on anti-cancer drug discovery. 2: 167-74, 2007.
209)  Deeken JF, Figg WD, Bates SE, Sparreboom A.
Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
Anticancer Drugs. 18: 111-26, 2007.
210)  Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, Figg WD, Verweij J, McLeod HL, Sparreboom A.
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.
Clin. Pharmacol. Ther. 81: 76-82, 2007.
211)  Luzzio F, Duveau D, Figg W.
A Chiral Pool Approach Toward the Synthesis of Thalidomide Metabolites.
Heterocycles. 70: 321-334, 2006.
212)  De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Farree X, Fine SW, Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA, Shah RB, Shah RB, Signoretti S, Simko J, Thomas G, Troncoso P, Tsuzuki TT, van Leenders GJ, Yang XJ, Zhou M, Figg WD, Hoque A, Hoque A, Lucia MS.
A working group classification of focal prostate atrophy lesions.
Am. J. Surg. Pathol. 30: 1281-91, 2006.
213)  Sartor O, Alchalabi T, Figg WD.
Assessing progress against prostate cancer.
Clinical genitourinary cancer. 5: 102-3, 2006.
214)  Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S.
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
Eur J Cancer. 2006.
215)  Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K.
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
Clin. Pharmacol. Ther. 80: 192-201, 2006.
216)  Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, Begg CB, Caporaso N, Chanock S, DeMichele A, Figg WD, Gospodarowicz MK, Hall EJ, Hisada M, Inskip P, Kleinerman R, Little JB, Malkin D, Ng AK, Offit K, Pui CH, Robison LL, Rothman N, Shields PG, Strong L, Taniguchi T, Tucker MA, Greene MH.
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations.
J. Natl. Cancer Inst. 98: 15-25, 2006.
217)  Parnes HL, Figg WD.
Chemoprevention in prostate cancer.
Pharmacotherapy. 26: 1533; author reply 1533, 2006.
218)  Gardner ER, Liau C, Chu ZE, Figg WD, Sparreboom A.
Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography/tandem mass spectrometry.
Rapid Commun Mass Spectrom. 20: 2170-2174, 2006.
Full Text Article. [Journal]
219)  Hwang K, Scripture CD, Gutierrez M, Kummar S, Figg WD, Sparreboom A.
Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830: 35-40, 2006.
220)  Ockers S, Price DK, Figg WD.
DNA microarrays: tissue removal and processing affects gene expression.
Cancer Biol. Ther. 5: 1608-9, 2006.
221)  Scripture CD, Figg WD.
Drug interactions in cancer therapy.
Nat. Rev. Cancer. 6: 546-58, 2006.
222)  Ahlers CM, Figg WD.
ETS-TMPRSS2 Fusion Gene Products in Prostate Cancer.
Cancer Biol. Ther. 5: 254-5, 2006.
223)  Singh AS, Macpherson GR, Price DK, Schimel D, Figg WD.
Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis.
Oncol. Rep. 15: 519-24, 2006.
224)  Gulley JL, Figg WD, Dahut W.
Even more cost savings?.
J Oncol Pract. 2: 202, 2006.
225)  Acharya MR, Karp JE, Sausville EA, Hwang K, Ryan Q, Gojo I, Venitz J, Figg WD, Sparreboom A.
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Investigational new drugs. 24: 367-75, 2006.
226)  Figg WD, Chau CH.
Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokinetics.
Cancer Biol. Ther. 5: 840-1, 2006.
227)  Sparreboom A, Figg WD.
Identifying sources of interindividual pharmacokinetic variability with population modeling.
Clin. Cancer Res. 12: 1951-3, 2006.
228)  Warfel NA, Lepper ER, Zhang C, Figg WD, Dennis PA.
Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells.
Clin. Cancer Res. 12: 3502-9, 2006.
229)  Ng SS, Sparreboom A, Shaked Y, Lee C, Man S, Desai N, Soon-Shiong P, Figg WD, Kerbel RS.
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
Clin. Cancer Res. 12: 4331-8, 2006.
230)  Cox MC, Low J, Lee J, Walshe J, Denduluri N, Berman A, Permenter MG, Petros WP, Price DK, Figg WD, Sparreboom A, Swain SM.
Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
Clin. Cancer Res. 12: 4636-40, 2006.
231)  Sion AM, Figg WD.
Lysyl Oxidase (LOX) and Hypoxia-Induced Metastases.
Cancer Biol Ther. 5, 2006.
232)  Scripture CD, Figg WD, Sparreboom A.
Peripheral neuropathy induced by Paclitaxel: recent insights and future perspectives.
Current neuropharmacology. 4: 165-72, 2006.
233)  Sissung TM, Price DK, Sparreboom A, Figg WD.
Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention.
Mol. Cancer Res. 4: 135-50, 2006.
234)  Smith NF, Figg WD, Sparreboom A.
Pharmacogenetics of irinotecan metabolism and transport: an update.
Toxicol In Vitro. 20: 163-75, 2006.
Full Text Article. [Journal]
235)  Gardner E, Figg W, Sparreboom A.
Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2.
Current Pharmacogenomics. 4: 331-4, 2006.
236)  Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD.
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
Cancer Biol. Ther. 5: 22-7, 2006.
237)  Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, Figg WD, Murgo AJ, Steinberg SM.
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
Clin. Cancer Res. 12: 5777-85, 2006.
238)  Smith EK, Price DK, Figg WD.
Piecing together the HIF-1 puzzle: the role of the CTGF as a molecular mechanism of HIF-1 regulation.
Cancer Biol. Ther. 5: 1443-4, 2006.
239)  Lakhani N, Sparreboom A, Venitz J, Dahut WL, Figg WD.
Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol.
Anticancer Drugs. 17: 977-83, 2006.
240)  Figg WD, Ockers S.
Prostate cancer - 6th International Congress.
IDrugs : the investigational drugs journal. 9: 675-8, 2006.
241)  Rozhansky F, Chen MH, Cox MC, Dahut W, Figg WD, D'Amico AV.
Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.
Cancer. 106: 63-7, 2006.
242)  Jain L, Venitz J, Figg WD.
Randomized Discontinuation Trial of Sorafenib (BAY 43-9006).
Cancer Biol Ther. 5, 2006.
243)  Figg WD, Dunn L, Liewehr DJ, Steinberg SM, Thurman PW, Barrett JC, Birkinshaw J.
Scientific collaboration results in higher citation rates of published articles.
Pharmacotherapy. 26: 759-67, 2006.
244)  Ge Y, Montano I, Rustici G, Freebern WJ, Haggerty CM, Cui W, Ponciano-Jackson D, Chandramouli GV, Gardner ER, Figg WD, Abu-Asab M, Tsokos M, Jackson SH, Gardner K.
Selective leukemic cell killing by a novel functional class of thalidomide analogs.
Blood. 2006.
245)  Ahlers C, Figg W.
Sifting Through the Multitude of Novel Therapies for Prostate Cancer.
Oncology. 20: 1792-6, 2006.
246)  Lepper ER, Smith NF, Cox MC, Scripture CD, Figg WD.
Thalidomide metabolism and hydrolysis: mechanisms and implications.
Curr. Drug Metab. 7: 677-85, 2006.
247)  Figg WD.
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer.
Clin. Pharmacol. Ther. 79: 1-8, 2006.
248)  Beverage JN, Figg WD.
The quantification of PSA mRNA copies in pathologically normal pelvic lymph nodes is a viable prognostic indicator.
Cancer Biol. Ther. 5: 1094-5, 2006.
249)  Scripture CD, Figg WD, Sparreboom A.
The role of drug-metabolising enzymes in clinical responses to chemotherapy.
Expert Opin Drug Metab Toxicol. 2: 17-25, 2006.
250)  Cox MC, Dahut WL, Figg WD.
The use of thalidomide in androgen-independent prostate cancer.
Urol. Oncol. 24: 246-9, 2006.
251)  Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee MJ, Chung EJ, Trepel JB, Sparreboom A, Chen C, Jones E, Steinberg SM, Daniels A, Figg WD, Dahut WL.
A phase II study of perifosine in androgen independent prostate cancer.
Cancer Biol. Ther. 4: 1133-7, 2005.
252)  Gulley JL, Figg WD, Steinberg SM, Carter J, Sartor O, Higano CS, Petrylak DP, Chatta G, Hussain MH, Dahut WL.
A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
J Urol. 173: 1567-71, 2005.
253)  Figg WD, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ, Cox MC, Zhai S, Cremers S, Parr A, Yang X, Chen CC, Jones E, Dahut WL.
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
J Urol. 173: 790-6, 2005.
254)  Sharifi N, Dahut WL, Steinberg SM, Figg WD, Tarassoff C, Arlen P, Gulley JL.
A retrospective study of the time to clinical endpoints for advanced prostate cancer.
BJU international. 96: 985-9, 2005.
255)  Cox MC, Permenter M, Figg WD.
Angiogenesis and prostate cancer: important laboratory and clinical findings.
Curr Oncol Rep. 7: 215-9, 2005.
256)  Longoria RL, Cox MC, Figg WD.
Antiangiogenesis: a possible treatment option for prostate cancer?.
Clinical genitourinary cancer. 4: 197-202, 2005.
257)  Kumar S, Raje N, Hideshima T, Ishitsuka K, Roccaro A, Shiraishi N, Hamasaki M, Yasui H, Munshi NC, Richardson P, Figg WD, Anderson KC.
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.
Leukemia. 19: 1253-61, 2005.
258)  Scripture CD, Szebeni J, Loos WJ, Figg WD, Sparreboom A.
Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
Cancer Biol Ther. 4: 555-60, 2005.
259)  Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N.
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Clin Cancer Res. 11: 4136-43, 2005.
260)  Tkacz VL, Tohnya TM, Figg WD.
Cyclooxygenase-2 and angiogenesis in prostate cancer.
Cancer Biol. Ther. 4: 813-4, 2005.
261)  Lakhani NJ, Lepper ER, Sparreboom A, Dahut WL, Venitz J, Figg WD.
Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry.
Rapid Commun Mass Spectrom. 19: 1176-82, 2005.
262)  Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, Nooter K, Gelderblom H.
Effect of ABCG2 Genotype on the Oral Bioavailability of Topotecan.
Cancer Biol Ther. 4: 650-8, 2005.
263)  Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A.
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Clin. Cancer Res. 11: 7398-404, 2005.
264)  Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A.
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel.
Cancer Biol. Ther. 4: 815-8, 2005.
265)  Singh AS, Figg WD.
In vivo models of prostate cancer metastasis to bone.
J Urol. 174: 820-6, 2005.
266)  Acharya MR, Sparreboom A, Sausville EA, Conley BA, Doroshow JH, Venitz J, Figg WD.
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
Cancer Chemother Pharmacol. 1-7, 2005.
267)  Cox MC, Scripture CD, Figg WD.
Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?.
Expert Rev Anticancer Ther. 5: 605-11, 2005.
268)  Singh AS, Chau CH, Price DK, Figg WD.
Mechanisms of disease: polymorphisms of androgen regulatory genes in the development of prostate cancer.
Nature Clin Pract Urol. 2: 101-7, 2005.
269)  Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A.
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.
Pharmacogenomics. 6: 115-38, 2005.
270)  Palmieri D, Halverson DO, Ouatas T, Horak CE, Salerno M, Johnson J, Figg WD, Hollingshead M, Hursting S, Berrigan D, Steinberg SM, Merino MJ, Steeg PS.
Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer.
J Natl Cancer Inst. 97: 632-42, 2005.
271)  Scripture CD, Sparreboom A, Figg WD.
Modulation of cytochrome P450 activity: implications for cancer therapy.
The lancet oncology. 6: 780-9, 2005.
272)  Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, González S, Velasco A, Linehan WM, Matusik RJ, Price DK, Figg WD, Emmert-Buck MR, Chuaqui RF.
Molecular alterations in primary prostate cancer after androgen ablation therapy.
Clin. Cancer Res. 11: 6823-34, 2005.
273)  Chau CH, Figg WD.
Molecular and phenotypic heterogeneity of metastatic prostate cancer.
Cancer Biol Ther. 4: 166-7, 2005.
274)  Scripture CD, Figg WD, Sparreboom A.
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
Therapeutics and clinical risk management. 1: 107-14, 2005.
275)  Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA.
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
J Clin Oncol. 23: 3912-22, 2005.
276)  Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD, Zhai S, Beresneva T, Seidel GD, Alexander HR.
Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies.
J Clin Oncol. 23: 3465-74, 2005.
277)  Chau CH, Permenter MG, Steinberg SM, Retter AS, Dahut WL, Price DK, Figg WD.
Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer.
Cancer Biol. Ther. 4: 1222-5, 2005.
278)  D'Amico AV, Chen MH, Cox MC, Dahut W, Figg WD.
Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
Urology. 66: 571-6, 2005.
279)  Acharya MR, Sparreboom A, Venitz J, Figg WD.
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
Mol. Pharmacol. 68: 917-32, 2005.
280)  Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J, Sparreboom A.
Relationship of systemic exposure to unbound docetaxel and neutropenia.
Clin. Pharmacol. Ther. 77: 43-53, 2005.
281)  Fuse E, Kuwabara T, Sparreboom A, Sausville EA, Figg WD.
Review of UCN-01 development: a lesson in the importance of clinical pharmacology.
J Clin Pharmacol. 45: 394-403, 2005.
282)  Smith NF, Figg WD, Sparreboom A.
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.
Expert opinion on drug metabolism & toxicology. 1: 429-45, 2005.
283)  Luzzio FA, Duveau DY, Lepper ER, Figg WD.
Synthesis of racemic cis-5-hydroxy-3-phthalimidoglutarimide. A metabolite of thalidomide isolated from human plasma.
J. Org. Chem. 70: 10117-20, 2005.
284)  Tohnya TM, Ng SS, Dahut WL, Wright JJ, Arlen PM, Gulley JL, Parker C, Zeldis J, Figg WD.
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
Clin Prostate Cancer. 2: 241-3, 2004.
285)  Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, Balis F, Figg WD, Fojo T.
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
Clin Cancer Res. 10: 4724-33, 2004.
286)  Ng SS, MacPherson GR, Gütschow M, Eger K, Figg WD.
Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
Clin. Cancer Res. 10: 4192-7, 2004.
287)  Acharya MR, Venitz J, Figg WD, Sparreboom A.
Chemically modified tetracyclines as inhibitors of matrix metalloproteinases.
Drug Resist Updat. 7: 195-208, 2004.
288)  Lepper ER, Ng SS, Gütschow M, Weiss M, Hauschildt S, Hecker TK, Luzzio FA, Eger K, Figg WD.
Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors.
J Med Chem. 47: 2219-27, 2004.
289)  Tohnya TM, Hwang K, Lepper ER, Fine HA, Dahut WL, Venitz J, Sparreboom A, Figg WD.
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci. 811: 135-41, 2004.
290)  Acharya MR, Baker SD, Verweij J, Figg WD, Sparreboom A.
Determination of fraction unbound docetaxel using microequilibrium dialysis.
Anal Biochem. 331: 192-4, 2004.
291)  Lepper ER, Hicks JK, Verweij J, Zhai S, Figg WD, Sparreboom A.
Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 806: 305-10, 2004.
292)  Hwang K, Acharya MR, Sausville EA, Zhai S, Woo EW, Venitz J, Figg WD, Sparreboom A.
Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci. 804: 289-94, 2004.
293)  Tohnya TM, Kim S, Fine HA, Dunn L, Figg WD, Sparreboom A.
Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography.
J Chromatogr B Analyt Technol Biomed Life Sci. 805: 135-40, 2004.
294)  Lakhani NJ, Sparreboom A, Dahut WL, Venitz J, Figg WD.
Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection.
J Chromatogr B Analyt Technol Biomed Life Sci. 806: 289-93, 2004.
295)  Hwang K, Piekarz RL, Bates SE, Figg WD, Sparreboom A.
Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci. 809: 81-6, 2004.
296)  Sparreboom A, Chen H, Acharya MR, Senderowicz AM, Messmann RA, Kuwabara T, Venzon DJ, Murgo AJ, Headlee D, Sausville EA, Figg WD.
Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
Clin Cancer Res. 10: 6840-6, 2004.
297)  Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM.
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
J Clin Oncol. 22: 3080-90, 2004.
298)  Price DK, Franks ME, Figg WD.
Genetic variations in the vitamin D receptor, androgen receptor and enzymes that regulate androgen metabolism.
J Urol. 171: S45-9; discussion S49, 2004.
299)  Macpherson GR, Singh AS, Bennett CL, Venzon DJ, Liewehr DJ, Franks ME, Dahut WL, Kantoff PW, Price DK, Figg WD.
Genotyping and functional analysis of the D104N variant of human endostatin.
Cancer Biol Ther. 3: 1298-303, 2004.
300)  Figg WD, Franks ME, Venzon D, Duray P, Cox MC, Linehan WM, Van Bingham W, Eastham JA, Reed E, Sartor O.
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.
World J Urol. 22: 425-30, 2004.
301)  Sparreboom A, Cox MC, Acharya MR, Figg WD.
Herbal remedies in the United States: potential adverse interactions with anticancer agents.
J Clin Oncol. 22: 2489-503, 2004.
302)  Acharya MR, Figg WD.
Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue.
Cancer Biol Ther. 3: 719-20, 2004.
303)  Paoluzzi L, Figg WD.
Histone deacetylase inhibitors are potent radiation protectants.
Cancer Biol Ther. 3: 612-3, 2004.
304)  Price DK, Figg WD.
hTert-immortalized endothelial cells: an important new research tool.
Cell Cycle. 3: 789, 2004.
305)  Tohnya TM, Figg WD.
Immunomodulation of multiple myeloma.
Cancer Biol Ther. 3: 1060-1, 2004.
306)  Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, Figg WD, Sparreboom A.
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
J Clin Pharmacol. 44: 854-60, 2004.
307)  Ehrlich A, Booher S, Becerra Y, Borris DL, Figg WD, Turner ML, Blauvelt A.
Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study.
J Am Acad Dermatol. 50: 533-40, 2004.
308)  Price DK, Figg WD.
Mutations in the EGFR: the importance of genotyping.
Cancer Biol Ther. 3: 434-5, 2004.
309)  Cox MC, Figg WD, Thurman PW.
No rational theory for drug pricing.
J Clin Oncol. 22: 962-3, 2004.
310)  Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C, Brahim JS, Steinberg SM, Figg WD, Swain SM.
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Clin Cancer Res. 10: 5038-47, 2004.
311)  Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A.
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
J Natl Cancer Inst. 96: 1585-92, 2004.
312)  Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD.
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
J Clin Oncol. 22: 2532-9, 2004.
313)  McDonald DM, Teicher BA, Stetler-Stevenson W, Ng SS, Figg WD, Folkman J, Hanahan D, Auerbach R, O'Reilly M, Herbst R, Cheresh D, Gordon M, Eggermont A, Libutti SK.
Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring.
J Immunother. 27: 161-75, 2004.
314)  Macpherson GR, Figg WD.
Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade.
Cancer Biol Ther. 3: 503-4, 2004.
315)  Ng SS, Figg WD, Sparreboom A.
Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.
Cancer Res. 64: 821-4, 2004.
316)  Franks ME, Macpherson GR, Figg WD.
Lancet. 363: 1802-11, 2004.
317)  Ng SS, Figg WD.
Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy.
Cancer Biol Ther. 3: 1212-3, 2004.
318)  Singh A, Figg WD.
Upregulation of the androgen receptor during prostate cancer progression.
Cancer Biol Ther. 3: 284-5, 2004.
319)  Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, Figg WD, Albert PS, Ménard C, Camphausen K.
Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy.
J Clin Oncol. 22: 499-506, 2004.
320)  Lakhani NJ, Sarkar MA, Venitz J, Figg WD.
2-Methoxyestradiol, a promising anticancer agent.
Pharmacotherapy. 23: 165-72, 2003.
321)  Uchio EM, Linehan WM, Figg WD, Walther MM.
A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.
J Urol. 169: 357-60, 2003.
322)  Hamilton M, Dahut W, Brawley O, Davis P, Wells-Jones T, Kohler D, Duray P, Liewehr DJ, Lakhani N, Steinberg SM, Figg WD, Reed E.
A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer.
Acta Oncol. 42: 195-201, 2003.
323)  Macpherson GR, Ng SS, Forbes SL, Melillo G, Karpova T, McNally J, Conrads TP, Veenstra TD, Martinez A, Cuttitta F, Price DK, Figg WD.
Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay.
Mol Cancer Ther. 2: 845-54, 2003.
324)  Ng SS, Gütschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K, Figg WD.
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
Cancer Res. 63: 3189-94, 2003.
325)  Ng SS, Figg WD.
Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient mice.
Anticancer Res. 23: 3585-90, 2003.
326)  Zhai S, Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann RA, Arbuck S, Murgo AJ, Melillo G, Fuse E, Figg WD.
Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.
Anticancer Drugs. 14: 125-35, 2003.
327)  Rudek MA, Bauer KS, Lush RM, Stinson SF, Senderowicz AM, Headlee DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, Figg WD.
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
Ann Pharmacother. 37: 1369-74, 2003.
328)  Macpherson GR, Franks M, Tomoaia-Cotisel A, Ando Y, Price DK, Figg WD.
Current status of thalidomide and its role in the treatment of metastatic prostate cancer.
Crit Rev Oncol Hematol. 46 Suppl: S49-57, 2003.
329)  Ten Tije AJ, Loos WJ, Verweij J, Baker SD, Dinh K, Figg WD, Sparreboom A.
Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches.
Clin Pharmacol Ther. 74: 509-10, 2003.
330)  Leonard GD, Dahut WL, Gulley JL, Arlen PM, Figg WD.
Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer.
Rev Urol. 5 Suppl 3: S65-70, 2003.
331)  Rudek MA, Venitz J, Ando Y, Reed E, Pluda JM, Figg WD.
Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies.
J Clin Pharmacol. 43: 1124-35, 2003.
332)  Messmann RA, Ullmann CD, Lahusen T, Kalehua A, Wasfy J, Melillo G, Ding I, Headlee D, Figg WD, Sausville EA, Senderowicz AM.
Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.
Clin Cancer Res. 9: 562-70, 2003.
333)  Horne MK, Figg WD, Arlen P, Gulley J, Parker C, Lakhani N, Parnes H, Dahut WL.
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
Pharmacotherapy. 23: 315-8, 2003.
334)  Lepper ER, Swain SM, Tan AR, Figg WD, Sparreboom A.
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor.
J Chromatogr B Analyt Technol Biomed Life Sci. 796: 181-8, 2003.
335)  Passaro MD, Piquion J, Mullen N, Sutherland D, Zhai S, Figg WD, Blye R, Nieman LK.
Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women.
Hum Reprod. 18: 1820-7, 2003.
336)  Franks ME, Macpherson GR, Lepper ER, Figg WD, Sparreboom A.
New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology.
Drug Resist. Updat. 6: 301-12, 2003.
337)  Ando Y, Price DK, Dahut WL, Cox MC, Reed E, Figg WD.
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.
Cancer Biol Ther. 1: 669-73, 2003.
338)  Lakhani NJ, Venitz J, Figg WD, Sparreboom A.
Pharmacogenetics of estrogen metabolism and transport in relation to cancer.
Curr Drug Metab. 4: 505-13, 2003.
339)  Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD.
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.
Drug Resist Updat. 6: 71-84, 2003.
340)  Figg WD, Cox MC.
Pharmacy education: back to the basics?.
Pharmacotherapy. 23: 1381-90, 2003.
341)  Hussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, Zhai S, Steinberg SM, Raggio M, Oliver VK, Figg WD, Kohn EC.
Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.
J Clin Oncol. 21: 4356-63, 2003.
342)  Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB.
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
J Clin Oncol. 21: 2299-304, 2003.
343)  Luzzio FA, Mayorov AV, Ng SS, Kruger EA, Figg WD.
Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine.
J Med Chem. 46: 3793-9, 2003.
344)  Retter AS, Figg WD, Dahut WL.
The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer.
Clinical prostate cancer. 2: 153-9, 2003.
345)  Gulley J, Figg WD, Dahut WL.
Treatment options for androgen-independent prostate cancer.
Clinical advances in hematology & oncology : H&O. 1: 49-57, 2003.
346)  Kurdziel KA, Figg WD, Carrasquillo JA, Huebsch S, Whatley M, Sellers D, Libutti SK, Pluda JM, Dahut W, Reed E, Bacharach SL.
Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.
Mol Imaging Biol. 5: 86-93, 2003.
347)  Price DK, Ando Y, Kruger EA, Weiss M, Figg WD.
5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis.
Ther Drug Monit. 24: 104-10, 2002.
348)  Zhai S, Sausville E, Figg WD.
A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma.
Biomed Chromatogr. 16: 379-82, 2002.
349)  Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ, Hawkins MJ.
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.
J Exp Ther Oncol. 2: 325-32, 2002.
350)  Macpherson GR, Ng SS, Lakhani NJ, Price DK, Venitz J, Figg WD.
Antiangiogenesis therapeutic strategies in prostate cancer.
Cancer Metastasis Rev. 21: 93-106, 2002.
351)  Gulley J, Figg WD, Dahut WD.
Docetaxel plus Thalidomide in a Patient with Androgen-Independent Prostate Cancer: Case Report.
Case Studies in Prostate Cancer. 3: 1-7, 2002.
352)  Blagosklonny MV, Darzynkiewicz Z, Figg WD.
Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel.
Cancer Biol Ther. 1: 420-5, 2002.
353)  Zhai S, Senderowicz AM, Sausville EA, Figg WD.
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
Ann Pharmacother. 36: 905-11, 2002.
354)  Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y, Miller CB.
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Clin Cancer Res. 8: 963-70, 2002.
355)  Figg WD, Kruger EA, Price DK, Kim S, Dahut WD.
Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.
Invest New Drugs. 20: 183-94, 2002.
356)  Ando Y, Figg WD.
Irinotecan in small-cell lung cancer.
N Engl J Med. 346: 1414-5; author reply 1414-5, 2002.
357)  Neelapu S, Figg WD, Dahut W, Reed E.
Leptomeningeal carcinomatosis in metastatic prostate cancer.
South Med J. 95: 107-8, 2002.
358)  Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, Pluda JM, Figg WD, Krown SE, Dezube BJ.
Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.
J Clin Oncol. 20: 153-9, 2002.
359)  Rudek MA, Venitz J, Figg WD.
Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?.
Pharmacotherapy. 22: 705-20, 2002.
360)  Zogakis TG, Costouros NG, Kruger EA, Forbes S, He M, Qian M, Feldman AL, Figg WD, Alexander HR, Liu ET, Kohn EC, Libutti SK.
Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay.
Biotechniques. 33: 664-6, 668, 670, 2002.
361)  Arlen PM, Figg WD, Gulley J, Cox MC, Linehan WM, Dahut W.
National Cancer Institute intramural approach to advanced prostate cancer.
Clin Prostate Cancer. 1: 153-62, 2002.
362)  Schrump DS, Zhai S, Nguyen DM, Weiser TS, Fisher BA, Terrill RE, Flynn BM, Duray PH, Figg WD.
Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques.
J. Thorac. Cardiovasc. Surg. 123: 686-94, 2002.
363)  Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, Senderowicz AM.
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
J Clin Oncol. 20: 4074-82, 2002.
364)  Schrump DS, Nguyen DM, Kunst TE, Hancox A, Figg WD, Steinberg SM, Pishchik V, Becerra Y.
Phase I study of sequential deoxyazacytidine/depsipeptide infusion in patients with malignancies involving lungs or pleura.
Clin Lung Cancer. 4: 186-92, 2002.
365)  Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE.
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Clin Cancer Res. 8: 718-28, 2002.
366)  Bennett CL, Price DK, Kim S, Liu D, Jovanovic BD, Nathan D, Johnson ME, Montgomery JS, Cude K, Brockbank JC, Sartor O, Figg WD.
Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status.
J Clin Oncol. 20: 3599-604, 2002.
367)  Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T.
Reversal of multidrug resistance: lessons from clinical oncology.
Novartis Found Symp. 243: 83-96; discussion 96-102, 180-5, 2002.
368)  Kaur M, Reed E, Sartor O, Dahut W, Figg WD.
Suramin's development: what did we learn?.
Invest New Drugs. 20: 209-19, 2002.
369)  Ando Y, Fuse E, Figg WD.
Thalidomide metabolism by the CYP2C subfamily.
Clin Cancer Res. 8: 1964-73, 2002.
370)  Ng SS, Brown M, Figg WD.
Thalidomide, an antiangiogenic agent with clinical activity in cancer.
Biomed Pharmacother. 56: 194-9, 2002.
371)  Béliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pépin MC, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E.
The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
Clin Cancer Res. 8: 1242-50, 2002.
372)  Cude KJ, Montgomery JS, Price DK, Dixon SC, Kincaid RL, Kovacs KF, Venzon DJ, Liewehr DJ, Johnson ME, Reed E, Figg WD.
The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer.
Urol Int. 68: 16-23, 2002.
373)  Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA.
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
Clin Cancer Res. 7: 2292-300, 2001.
374)  Bates S, Kang M, Meadows B, Bakke S, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, Figg WD, Fojo T.
A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
Cancer. 92: 1577-90, 2001.
375)  Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick-Bruton F, Kulpa V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, Figg WD, Liotta LA.
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Clin Cancer Res. 7: 1600-9, 2001.
376)  Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL.
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
Semin Oncol. 28: 62-6, 2001.
377)  Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Krüger EA, Gubish E, Pluda JM, Reed E.
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Clin Cancer Res. 7: 1888-93, 2001.
378)  Carrasquillo JA, Whatley M, Dyer V, Figg WD, Dahut W.
Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.
J Nucl Med. 42: 1359-63, 2001.
379)  Kruger EA, Duray PH, Price DK, Pluda JM, Figg WD.
Approaches to preclinical screening of antiangiogenic agents.
Semin Oncol. 28: 570-6, 2001.
380)  Sunwoo JB, Herscher LL, Kroog GS, Thomas GR, Ondrey FG, Duffey DC, Solomon BI, Boss C, Albert PS, McCullugh L, Rudy S, Muir C, Zhai S, Figg WD, Cook JA, Mitchell JB, Van Waes C.
Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer.
J Clin Oncol. 19: 800-11, 2001.
381)  Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E.
Drug-induced lupus associated with COL-3: report of 3 cases.
Arch Dermatol. 137: 471-4, 2001.
382)  Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL.
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?.
J Pharmacol Exp Ther. 296: 537-41, 2001.
383)  Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Rowinsky EK, Zabalena Y, Hawkins AL, Burks K, Miller CB.
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Clin Cancer Res. 7: 2330-9, 2001.
384)  Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR.
Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
Surgery. 129: 176-87, 2001.
385)  Chang E, Alexander HR, Libutti SK, Hurst R, Zhai S, Figg WD, Bartlett DL.
Laparoscopic continuous hyperthermic peritoneal perfusion.
J Am Coll Surg. 193: 225-9, 2001.
386)  Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E.
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
J Clin Oncol. 19: 584-92, 2001.
387)  Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, Bates S.
Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
J Clin Oncol. 19: 832-42, 2001.
388)  Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM.
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
J Clin Oncol. 19: 2319-33, 2001.
389)  Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU.
Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer.
Clin Cancer Res. 7: 1198-203, 2001.
390)  Burstein AH, Reed E, Tompkins AC, Venzon D, Figg WD.
Phenylacetate pharmacokinetics based on iterative two-stage population analysis.
Pharmacotherapy. 21: 281-6, 2001.
391)  Krüger EA, Figg WD.
Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay.
Clin Cancer Res. 7: 1867-72, 2001.
392)  Woo EW, Messmann R, Sausville EA, Figg WD.
Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry.
J Chromatogr B Biomed Sci Appl. 759: 247-57, 2001.
393)  Blagosklonny MV, Dixon SC, Robey R, Figg WD.
Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines.
Int J Oncol. 18: 697-704, 2001.
394)  Rudek MA, Horne M, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E.
Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.
Am J Hematol. 67: 51-3, 2001.
395)  Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD.
Thalidomide neuropathy in patients treated for metastatic prostate cancer.
Muscle Nerve. 24: 1050-7, 2001.
396)  Montgomery JS, Price DK, Figg WD.
The androgen receptor gene and its influence on the development and progression of prostate cancer.
J Pathol. 195: 138-46, 2001.
397)  Dixon SC, Knopf KB, Figg WD.
The control of prostate-specific antigen expression and gene regulation by pharmacological agents.
Pharmacol Rev. 53: 73-91, 2001.
398)  Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM.
The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.
Leukemia. 15: 1537-43, 2001.
399)  Kang MH, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, Bates SE.
The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
Clin Cancer Res. 7: 1610-7, 2001.
400)  Bauer KS, Lush RM, Rudek MA, Shih C, Sausville E, Figg WD.
A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva.
Biomed Chromatogr. 14: 338-43, 2000.
401)  Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe ES, Stetler-Stevenson M, Chen H, Ghetie V, Sausville EA.
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Clin Cancer Res. 6: 1302-13, 2000.
402)  Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigal E, Steinberg SM, Whitby D, Goedert JJ, Yarchoan R.
Activity of thalidomide in AIDS-related Kaposi's sarcoma.
J Clin Oncol. 18: 2593-602, 2000.
403)  Bauer KS, Cude KJ, Dixon SC, Kruger EA, Figg WD.
Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway.
J Pharmacol Exp Ther. 292: 31-7, 2000.
404)  Thrasher JB, Deeths J, Bennett C, Iyer P, Dineen MK, Zhai S, Figg WD, McLeod DG.
Comparative study of the clinical efficacy of two dosing regimens of flutamide.
Mol Urol. 4: 259-63;discussion 265, 2000.
405)  Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW.
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.
Proc Natl Acad Sci U S A. 97: 10990-5, 2000.
406)  Blagosklonny MV, Dixon SC, Figg WD.
Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines.
J Urol. 163: 1022-6, 2000.
407)  Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Allegra C, Figg WD.
Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay.
Biochem Biophys Res Commun. 268: 183-91, 2000.
408)  Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, Turner E, Kruger E, Figg WD, Grove A, Kohn E, Stern D, Libutti SK.
Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
Microvasc Res. 60: 70-80, 2000.
409)  Rudek MA, March CL, Bauer KS, Pluda JM, Figg WD.
High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma.
J Pharm Biomed Anal. 22: 1003-14, 2000.
410)  Salnikow K, Costa M, Figg WD, Blagosklonny MV.
Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer.
Cancer Res. 60: 5630-4, 2000.
411)  Wilson WH, Sorbara L, Figg WD, Mont EK, Sausville E, Warren KE, Balis FM, Bauer K, Raffeld M, Senderowicz AM, Monks A.
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
Clin Cancer Res. 6: 415-21, 2000.
412)  Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK.
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
J Clin Oncol. 18: 708-15, 2000.
413)  Walther MM, Rehak NN, Venzon D, Myers CE, Linehan WM, Figg WD.
Suramin administration is associated with a decrease in serum calcium levels.
World J Urol. 18: 388-91, 2000.
414)  Luzzio FA, Thomas EM, Figg WD.
Thalidomide metabolites and analogs. Part II: Cyclic derivatives of 2-N phthalimido-2S,3S (3-hydroxy) ornithine.
Tetrahedron Letters. 41: 7151-5, 2000.
415)  Luzzio FA, Mayorov AV, Figg WD.
Thalidomide Metabolites I: Derivatives of (+)-2-(N-Phthalimido)-gamma- hydroxyglutamic acid.
Tetrahedron Letters. 41: 2275-2278, 2000.
416)  Berger AC, Feldman AL, Gnant MF, Kruger EA, Sim BK, Hewitt S, Figg WD, Alexander HR, Libutti SK.
The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing.
J. Surg. Res. 91: 26-31, 2000.
417)  Kruger EA, Figg WD.
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
Expert Opin Investig Drugs. 9: 1383-96, 2000.
418)  Bauer KS, Figg WD, Hamilton JM, Jones EC, Premkumar A, Steinberg SM, Dyer V, Linehan WM, Pluda JM, Reed E.
A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer.
Clin Cancer Res. 5: 2324-9, 1999.
419)  Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, Figg WD, Tompkins A, Linehan WM, Kohler D, Steinberg SM, Blagosklonny MV.
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
Clin. Cancer Res. 5: 2366-73, 1999.
420)  Senderowicz AM, Reid R, Headlee D, Abornathy T, Horti J, Lush RM, Reed E, Figg WD, Sausville EA.
A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer.
Urol Int. 63: 120-5, 1999.
421)  Figg WD, Blumenfeld JR.
Are we making an impact on prostate cancer?.
Prostate Cancer Prostatic Dis. 2: 60-61, 1999.
422)  Park BJ, Brown CK, Hu Y, Alexander HR, Horti J, Raje S, Figg WD, Bartlett DL.
Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma.
Hum Gene Ther. 10: 889-98, 1999.
423)  Melchior SW, Brown LG, Figg WD, Quinn JE, Santucci RA, Brunner J, Thüroff JW, Lange PH, Vessella RL.
Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo.
Int J Oncol. 14: 501-8, 1999.
424)  Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G.
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
J Clin Oncol. 17: 3461-7, 1999.
425)  Arah IN, Dixon SC, Horti J, Figg WD.
Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
Neoplasma. 46: 117-23, 1999.
426)  Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, Figg WD.
Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor.
Br J Cancer. 79: 1588-93, 1999.
427)  Saif MW, Figg WD, Hewitt S, Brosky K, Reed E, Dahut W.
Malignant ascites as only manifestation of metastatic prostate cancer.
Prostate Cancer Prostatic Dis. 2: 290-293, 1999.
428)  Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, Lee KB, Venzon DJ, Bauer KS, Reed E, Figg WD.
Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis.
J Clin Pharmacol. 39: 394-401, 1999.
429)  Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, Chen A, Hamilton M, Pluda J, Reed E.
Pharmacokinetics of thalidomide in an elderly prostate cancer population.
J Pharm Sci. 88: 121-5, 1999.
430)  Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames MM, Tong WP, Lim S, Figg WD.
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma.
Mayo Clin Proc. 74: 137-45, 1999.
431)  Lush RM, Rudek MA, Figg WD.
Review of Three New Agents That Target Angiogenesis, Matrix Metalloproteinases, and Cyclin-Dependent Kinases.
Cancer Control. 6: 459-465, 1999.
432)  Kang MH, Figg WD, Dahut W.
Taxanes in hormone-refractory prostate cancer.
Cancer Pract. 7: 270-2, 1999.
433)  Dixon SC, Kruger EA, Bauer KS, Figg WD.
Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.
Cancer Chemother Pharmacol. 43 Suppl: S78-84, 1999.
434)  Cude KJ, Dixon SC, Guo Y, Lisella J, Figg WD.
The androgen receptor: genetic considerations in the development and treatment of prostate cancer.
J Mol Med. 77: 419-26, 1999.
435)  Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD.
Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
Clin Cancer Res. 5: 1738-44, 1999.
436)  Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, Figg WD, Venzon DJ, Alexander HR.
A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
Cancer. 83: 1251-61, 1998.
437)  Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, Reed E, Samid D.
A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer.
Tumori. 84: 87-9, 1998.
438)  Horti J, Figg WD, Weinberger B, Kohler D, Sartor O.
A phase II study of bromocriptine in patients with androgen-independent prostate cancer.
Oncol Rep. 5: 893-6, 1998.
439)  Piscitelli SC, Vogel S, Figg WD, Raje S, Forrest A, Metcalf JA, Baseler M, Falloon J.
Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus.
Pharmacotherapy. 18: 1212-6, 1998.
440)  Alexander HR, Brown CK, Bartlett DL, Libutti SK, Figg WD, Raje S, Turner E.
Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms.
Clin Cancer Res. 4: 2357-62, 1998.
441)  Sausville EA, Lush RD, Headlee D, Smith AC, Figg WD, Arbuck SG, Senderowicz AM, Fuse E, Tanii H, Kuwabara T, Kobayashi S.
Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models.
Cancer Chemother Pharmacol. 42 Suppl: S54-9, 1998.
442)  Sartor O, Weinberger M, Moore A, Li A, Figg WD.
Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer.
Urology. 52: 252-6, 1998.
443)  Feuer JA, Lush RM, Venzon D, Duray P, Tompkins A, Sartor O, Figg WD.
Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer.
J Investig Med. 46: 66-72, 1998.
444)  Bauer KS, Dixon SC, Figg WD.
Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent.
Biochem Pharmacol. 55: 1827-34, 1998.
445)  Dixon SC, Horti J, Guo Y, Reed E, Figg WD.
Methods for extracting and amplifying genomic DNA isolated from frozen serum.
Nat Biotechnol. 16: 91-4, 1998.
446)  Bauer KS, Kohn EC, Lush RM, Steinberg SM, Davis P, Kohler D, Reed E, Figg WD.
Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters.
J Pharmacokinet Biopharm. 26: 673-87, 1998.
447)  Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA.
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
J. Clin. Oncol. 16: 2986-99, 1998.
448)  Dawson N, Figg WD, Brawley OW, Bergan R, Cooper MR, Senderowicz A, Headlee D, Steinberg SM, Sutherland M, Patronas N, Sausville E, Linehan WM, Reed E, Sartor O.
Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Clin. Cancer Res. 4: 37-44, 1998.
449)  Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill KM, Feuerstein I, Figg WD, Lush R, Odom J, Wilson WH, Fajardo MT, Humphrey RW, Feigal E, Tuck D, Steinberg SM, Broder S, Yarchoan R.
Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.
J Clin Oncol. 16: 1112-21, 1998.
450)  Kruger EA, Blagosklonny MV, Dixon SC, Figg WD.
UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response.
Invasion Metastasis. 18: 209-18, 1998.
451)  Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S.
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
Cancer Res. 58: 3248-53, 1998.
452)  Dixon SC, Soriano BJ, Lush RM, Borner MM, Figg WD.
Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target.
Ann Pharmacother. 31: 76-82, 1997.
453)  Senderowicz AM, Vitetta E, Headlee D, Ghetie V, Uhr JW, Figg WD, Lush RM, Stetler-Stevenson M, Kershaw G, Kingma DW, Jaffe ES, Sausville EA.
Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
Ann Intern Med. 126: 882-5, 1997.
454)  Ma GY, Bartlett DL, Reed E, Figg WD, Lush RM, Lee KB, Libutti SK, Alexander HR.
Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.
Cancer J Sci Am. 3: 174-9, 1997.
455)  Figg WD, Kroog G, Duray P, Walther MM, Patronas N, Sartor O, Reed E.
Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
Cancer. 79: 1964-8, 1997.
456)  Dixon SC, Zalles A, Giordano C, Lush RM, Venzon D, Reed E, Figg WD.
In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3.
Cancer Lett. 113: 111-6, 1997.
457)  Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, Figg WD.
Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.
J Clin Pharmacol. 37: 123-8, 1997.
458)  Figg WD, Feuer JA, Bauer KS.
Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy.
Cancer Pract. 5: 258-63, 1997.
459)  Masiero L, Figg WD, Kohn EC.
New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12.
Angiogenesis. 1: 23-35, 1997.
460)  Piscitelli SC, Reiss WG, Figg WD, Petros WP.
Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations.
Clin Pharmacokinet. 32: 368-81, 1997.
461)  Figg WD, Christian MC, Lush R, Link CJ, Davis P, Kohn E, Sarosy G, Rothenberg ML, Weiss RB, Ryan N, Jacobs J, Reed E.
Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.
Biopharm Drug Dispos. 18: 347-59, 1997.
462)  Piscitelli SC, Forrest A, Lush RM, Ryan N, Whitfield LR, Figg WD.
Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
Pharmacotherapy. 17: 431-7, 1997.
463)  Kohn EC, Figg WD, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, Thompkins A, Liotta LA, Reed E.
Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.
J Clin Oncol. 15: 1985-93, 1997.
464)  Dawson NA, Figg WD, Cooper MR, Sartor O, Bergan RC, Senderowicz AM, Steinberg SM, Tompkins A, Weinberger B, Sausville EA, Reed E, Myers CE.
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
J Clin Oncol. 15: 1470-7, 1997.
465)  Walsh TJ, Whitcomb P, Piscitelli S, Figg WD, Hill S, Chanock SJ, Jarosinski P, Gupta R, Pizzo PA.
Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.
Antimicrob Agents Chemother. 41: 1944-8, 1997.
466)  Bergan RC, Walls RG, Figg WD, Dawson NA, Headlee D, Tompkins A, Steinberg SM, Reed E.
Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer.
J Natl Med Assoc. 89: 622-8, 1997.
467)  Piscitelli SC, Figg WD, Hahn B, Kelly G, Thomas S, Walker RE.
Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients.
Antimicrob Agents Chemother. 41: 2797-9, 1997.
468)  Figg WD, Pluda JM, Lush RM, Saville MW, Wyvill K, Reed E, Yarchoan R.
The pharmacokinetics of TNP-470, a new angiogenesis inhibitor.
Pharmacotherapy. 17: 91-7, 1997.
469)  Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowicz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES.
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
Blood. 88: 1188-97, 1996.
470)  Lush RM, Figg WD, Pluda JM, Bitton R, Headlee D, Kohler D, Reed E, Sartor O, Cooper MR.
A phase I study of pentosan polysulfate sodium in patients with advanced malignancies.
Ann Oncol. 7: 939-44, 1996.
471)  Bowden CJ, Figg WD, Dawson NA, Sartor O, Bitton RJ, Weinberger MS, Headlee D, Reed E, Myers CE, Cooper MR.
A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Cancer Chemother Pharmacol. 39: 1-8, 1996.
472)  Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, Figg WD, Davis PA, Jacob J, Goldspiel B, Liotta LA.
Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.
Cancer Res. 56: 569-73, 1996.
473)  Figg WD, Dawson N, Middleman MN, Brawley O, Lush RM, Senderowicz A, Steinberg SH, Tompkins A, Reed E, Sartor O.
Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer.
Acta Oncol. 35: 763-5, 1996.
474)  Walther MM, Figg WD, Linehan WM.
Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.
World J Urol. 14 Suppl 1: S8-11, 1996.
475)  Figg WD, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson N, Reed E, Sartor O.
Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer.
Cancer Invest. 14: 513-7, 1996.
476)  Sartor O, Figg WD.
Mifepristone: antineoplastic studies.
Clin Obstet Gynecol. 39: 498-505, 1996.
477)  Figg WD, Dukes GE, Pritchard JF, Hermann DJ, Lesesne HR, Carson SW, Songer SS, Powell JR, Hak LJ.
Pharmacokinetics of ondansetron in patients with hepatic insufficiency.
J Clin Pharmacol. 36: 206-15, 1996.
478)  Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE.
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
Clin Cancer Res. 2: 483-91, 1996.
479)  Boudoulas S, Lush RM, McCall NA, Samid D, Reed E, Figg WD.
Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents.
Ther Drug Monit. 18: 714-20, 1996.
480)  Tisdale JF, Figg WD, Reed E, McCall NA, Alkins BR, Horne MK.
Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one.
Am J Hematol. 51: 152-7, 1996.
481)  Dawson NA, Lush RM, Steinberg SM, Tompkins AC, Headlee DJ, Figg WD.
Suramin-induced neutropenia.
Eur J Cancer. 32A: 1534-9, 1996.
482)  Walls R, Thibault A, Liu L, Wood C, Kozlowski JM, Figg WD, Sampson ML, Elin RJ, Samid D.
The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells.
Prostate. 29: 177-82, 1996.
483)  Middleman MN, Lush RM, Figg WD.
The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
Pharmacotherapy. 16: 376-81, 1996.
484)  Middleman MN, Lush RM, Sartor O, Reed E, Figg WD.
Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence.
Cancer Treat Rev. 22: 105-18, 1996.
485)  Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O.
A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.
Cancer. 75: 2159-64, 1995.
486)  Bitton RJ, Figg WD, Reed E.
A preliminary risk-benefit assessment of paclitaxel.
Drug Saf. 12: 196-208, 1995.
487)  Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O.
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
Cancer. 76: 453-62, 1995.
488)  Figg WD, Dukes GE, Lesesne HR, Carson SW, Songer SS, Pritchard JF, Hermann DJ, Powell JR, Hak LJ.
Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan.
Pharmacotherapy. 15: 693-700, 1995.
489)  Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM.
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.
Blood. 85: 3457-65, 1995.
490)  Piscitelli SC, Thibault A, Figg WD, Tompkins A, Headlee D, Lieberman R, Samid D, Myers CE.
Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine.
J Clin Pharmacol. 35: 368-73, 1995.
491)  Guetta V, Lush RM, Figg WD, Waclawiw MA, Cannon RO.
Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women.
Am J Cardiol. 76: 1072-3, 1995.
492)  Figg WD, Middleman M, Sartor O.
Mutated androgen receptors of prostate-cancer cells.
N. Engl. J. Med. 333: 1010-1, 1995.
493)  Danesi R, Figg WD, Reed E, Myers CE.
Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells.
Mol Pharmacol. 47: 1106-11, 1995.
494)  Figg WD, Cole KA, Reed E, Steinberg SM, Piscitelli SC, Davis PA, Soltis MJ, Jacob J, Boudoulas S, Goldspiel B.
Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction.
Clin Cancer Res. 1: 797-803, 1995.
495)  Bitton RJ, Figg WD, Venzon DJ, Dalakas MC, Bowden C, Headlee D, Reed E, Myers CE, Cooper MR.
Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
J Clin Oncol. 13: 2223-9, 1995.
496)  Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE.
Phase I study of phenylacetate administered twice daily to patients with cancer.
Cancer. 75: 2932-8, 1995.
497)  Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE.
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.
Am J Med. 98: 412-4, 1995.
498)  Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, Samid D.
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.
Cancer Res. 54: 1690-4, 1994.
499)  Figg WD, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC, Reed E, Sartor O.
Acute renal toxicity associated with suramin in the treatment of prostate cancer.
Cancer. 74: 1612-4, 1994.
500)  Figg WD, Stevens JA, Cooper MR.
Adaptive control with feedback of suramin using intermittent infusions.
J Clin Oncol. 12: 1523-4, 1994.
501)  Figg WD, Yeh HJ, Thibault A, Pluda JM, Itoh F, Yarchoan R, Cooper MR.
Assay of the antiangiogenic compound TNP-470, and one of its metabolites, AGM-1883, by reversed-phase high-performance liquid chromatography in plasma.
J Chromatogr. 652: 187-94, 1994.
502)  Foss FM, Borkowski TA, Gilliom M, Stetler-Stevenson M, Jaffe ES, Figg WD, Tompkins A, Bastian A, Nylen P, Woodworth T.
Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.
Blood. 84: 1765-74, 1994.
503)  Figg WD, Thibault A, Sartor AO, Mays D, Headlee D, Calis KA, Cooper MR.
Hypothyroidism associated with aminoglutethimide in patients with prostate cancer.
Arch Intern Med. 154: 1023-5, 1994.
504)  Figg WD, Walls RG, Cooper MR, Thibault A, Sartor O, McCall NA, Myers CE, Samid D.
In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate.
Anticancer Drugs. 5: 336-42, 1994.
505)  Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linehan WM, Myers CE.
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of.
J Natl Cancer Inst. 86: 222-7, 1994.
506)  Thibault A, Figg WD, Cooper MR, Prindiville SA, Sartor AO, Headlee DJ, Myers CE.
Anaphylactoid reaction with suramin.
Pharmacotherapy. 13: 656-7, 1993.
507)  Figg WD, Graham CL, Hak LJ, Dukes GE.
Ondansetron: a novel antiemetic agent.
South Med J. 86: 497-502, 1993.
508)  Figg WD.
Aseptic meningitis associated with muromonab-CD3.
DICP. 25: 1395, 1991.
509)  Bourge RC, Kirklin JK, Naftel DC, Figg WD, White-Williams C, Ketchum C.
Diltiazem-cyclosporine interaction in cardiac transplant recipients: impact on cyclosporine dose and medication costs.
Am J Med. 90: 402-4, 1991.
510)  O'Quinn SV, Figg WD.
Nitrate tolerance: does tid isosorbide dinitrate mean dosing every eight hours?.
DICP : the annals of pharmacotherapy. 25: 1272-3, 1991.
511)  Figg WD.
Ondansetron versus dexamethasone.
Lancet. 338: 946, 1991.
512)  Figg WD.
Peripheral neuropathy in HIV patient after isoniazid therapy initiated.
DICP. 25: 100-1, 1991.
513)  Thompson G, Figg WD.
Diarrhea precipitated by oral liquid medication.
Am J Med. 89: 697, 1990.
514)  Avent CK, Krinsky D, Kirklin JK, Bourge RC, Figg WD.
Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine.
Am J Med. 85: 452-3, 1988.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/1/2014.